XPOVIO® will be available in 600 hospitals and 105 DTPs (across China including Beijing, Shanghai, Guangdong, Jiangsu, Zhejiang, Henan, and Shandong). SHANGHAI and HONG KONG, May 15, 2022 /PRNewswire/ — Antengene…
Category: News
RoundGlass Living Highlights the Power of Music for Meditation in Honor of its World Meditation Day Celebration
RoundGlass Living, the app created by RoundGlass, a global Wholistic Wellbeing company dedicated to empowering people on…
Bamboo Rose Goes Live with The Vitamin Shoppe to Connect and Optimize Product Development and Sourcing
Bamboo Rose’s Product Lifecycle Management (PLM) and Sourcing applications will help the specialty retailer and wellness…
Respiratory Devices Market in Australia 2022-2026 | Increase in Patient Awareness to Boost Growth | Technavio
The Respiratory Devices Market size in Australia is expected to grow by USD 458.32 million from 2021 to 2026, at a CAGR of…
Minnesota Council of Health Plans Releases 2021 Industry Financial Results
Throughout the second year of the COVID-19 pandemic, Minnesota’snonprofit health plans continued to put the health and…
Blue Cross and Blue Shield of Minnesota Reports 2021 Financial Results
The Blue Cross and Blue Shield of Minnesota (Blue Cross) family of companies today announced audited financial results…
Seaweed Extracts Market Attracts Sizable Sales Prospects from Food Industry, States TMR Study
The global seaweed extracts market is estimated to register growth at a CAGR of 5% during the forecast…
Trevi Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference
– Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational oral therapy Haduvio™ (nalbuphine ER)…
Qualifacts + Credible Announces Partnership with Mental Health America of Los Angeles
– Qualifacts + Credible, a leading provider of electronic health record (EHR) platforms for behavioral health and human services organizations, today…
Gannex Announces First Patient Dosed in Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis
Gannex is expected to complete the Phase II trial in 100 patients by the end of…